Evidence map›Paper›PMID 40083079›Full record

ArticleCancer science2025

Features of HLA-A*02 in Identifying Eligible Patients for Tecelra TCR-T Therapy.

Min Yang, Peiluan Zhong, Huifang Jiao, Pengcheng Wei

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Min YangGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.ORCID https://orcid.org/0000-0003-4792-9493
Peiluan ZhongGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Huifang JiaoGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Pengcheng WeiGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.ORCID https://orcid.org/0000-0003-0002-9439

Funding

Guangxi University Science and Technology Multiplication Program for Cultivating Young Backbone Innovative Talents 2023BZRC014National Natural Science Foundation of China 32000611Natural Science Foundation of Guangxi Zhuang Autonomous Region 2023GXNSFAA026039Natural Science Foundation of Guangxi Zhuang Autonomous Region 2024GXNSFBA010423
6 · The paper itself

Abstract

This study investigates the molecular mechanisms behind HLA-A*02 subtypes' differential responses to Tecelra, a TCR-engineered T-cell therapy targeting MAGE-A4. Using computational tools, the study identifies specific HLA-A*02 alleles, such as HLA-A*02:07, HLA-A*02:05, and others, with low affinity for the GV10 peptide or a risk of inducing alloreactivity. These findings provide insights into patient selection for Tecelra therapy, suggesting exclusion criteria for certain HLA-A*02 subtypes to optimize treatment efficacy and minimize adverse reactions.

Indexed as

HLA-A2 AntigenImmunotherapy, AdoptiveReceptors, Antigen, T-CellReceptors, Chimeric AntigenAllelesAntigens, NeoplasmHumansNeoplasm ProteinsAntigens, NeoplasmHLA-A*02 antigenHLA-A2 AntigenNeoplasm ProteinsReceptors, Antigen, T-CellReceptors, Chimeric Antigen

Identifiers

PMID40083079
PMCPMC12317396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.